John Matthew Maris, M.D.

faculty photo
Professor of Pediatrics
Department: Pediatrics
Graduate Group Affiliations

Contact information
The Children's Hospital of Philadelphia
Division of Oncology
Colket Translational Research Building
3501 Civic Center Boulevard #3060

4399
Philadelphia, PA 19104-4318
Office: 215 590 5244
Fax: 267 426 0685
Education:
B.S. (Biology)
Wheeling College , 1983.
M.D. (Medicine)
University of Pennsylvania, 1989.
Permanent link
 

Selected Publications

Kolb E Anders, Gorlick Richard, Reynolds C Patrick, Kang Min H, Carol Hernan, Lock Richard, Keir Stephen T, Maris John M, Billups Catherine A, Desjardins Christopher, Kurmasheva Raushan T, Houghton Peter J, Smith Malcolm A: Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood & Cancer 60(8): 1325-32, Aug 2013.

Wang Larry L, Suganuma Rie, Ikegaki Naohiko, Tang Xao, Naranjo Arlene, McGrady Patrick, London Wendy B, Hogarty Michael D, Gastier-Foster Julie M, Look A Thomas, Park Julie R, Maris John M, Cohn Susan L, Seeger Robert C, Shimada Hiroyuki: Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. Cancer Jul 2013.

Kreissman Susan G, Seeger Robert C, Matthay Katherine K, London Wendy B, Sposto Richard, Grupp Stephan A, Haas-Kogan Daphne A, Laquaglia Michael P, Yu Alice L, Diller Lisa, Buxton Allen, Park Julie R, Cohn Susan L, Maris John M, Reynolds C Patrick, Villablanca Judith G: Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. The Lancet Oncology Jul 2013.

Maurer Barry J, Kang Min H, Villablanca Judith G, Janeba Jitka, Groshen Susan, Matthay Katherine K, Sondel Paul M, Maris John M, Jackson Hollie A, Goodarzian Fariba, Shimada Hiroyuki, Czarnecki Scarlett, Hasenauer Beth, Reynolds C Patrick, Marachelian Araz: Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium. Pediatric Blood & Cancer Jun 2013.

Wood Andrew C, Maris John M, Gorlick Richard, Kolb E Anders, Keir Stephen T, Reynolds C Patrick, Kang Min H, Wu Jianrong, Kurmasheva Raushan T, Whiteman Kathleen, Houghton Peter J, Smith Malcolm A: Initial testing (stage 1) of the antibody-maytansinoid conjugate, IMGN901 (lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatric Blood & Cancer Jun 2013.

Mosse Yael P, Lim Megan S, Voss Stephan D, Wilner Keith, Ruffner Katherine, Laliberte Julie, Rolland Delphine, Balis Frank M, Maris John M, Weigel Brenda J, Ingle Ashish M, Ahern Charlotte, Adamson Peter C, Blaney Susan M: Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. The Lancet Oncology 14(6): 472-80, May 2013.

Yanik Gregory A, Parisi Marguerite T, Shulkin Barry L, Naranjo Arlene, Kreissman Susan G, London Wendy B, Villablanca Judith G, Maris John M, Park Julie R, Cohn Susan L, McGrady Patrick, Matthay Katherine K: Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Journal of Nuclear Medicine 54(4): 541-8, Apr 2013.

Suganuma Rie, Wang Larry L, Sano Hideki, Naranjo Arlene, London Wendy B, Seeger Robert C, Hogarty Michael D, Gastier-Foster Julie M, Look A Thomas, Park Julie R, Maris John M, Cohn Susan L, Amann Gabriele, Beiske Klaus, Cullinane Catherine J, d'Amore Emanuele S G, Gambini Claudio, Jarzembowski Jason A, Joshi Vijay V, Navarro Samuel, Peuchmaur Michel, Shimada Hiroyuki: Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatric Blood & Cancer 60(3): 363-70, Mar 2013.

Mayes Patrick A, Degenhardt Yan Y, Wood Andrew, Toporovskya Yana, Diskin Sharon J, Haglund Elizabeth, Moy Christopher, Wooster Richard, Maris John M: Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. International Journal of Cancer 132(3): E149-57, Feb 2013.

Seif A E, Naranjo A, Baker D L, Bunin N J, Kletzel M, Kretschmar C S, Maris J M, McGrady P W, von Allmen D, Cohn S L, London W B, Park J R, Diller L R, Grupp S A: A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplantation Jan 2013.

back to top
Last updated: 08/22/2013
The Trustees of the University of Pennsylvania